A growing team of groundbreaking scientists around the world are now sharing their lab notebooks online
Background NSD3 is a member of the NSD (nuclear receptor SET domain- containing) family of H3K36 methyltransferases. It has two isoforms: long -1437 amino acid and short – 645 amino acids, which are derived from alternative splicing of exon 10. In contrast to long isoform, the short isoform lacks the methyltransferase domain and it contains Read More …
Background NSD2 is a member of the NSD (nuclear receptor SET domain- containing) family of H3K36 methyltransferases which contain a conserved catalytic SET domain and several chromatin-associated domains comprising four PHD fingers, two PWWP domains, and an HMG box. NSD2 is implicated in several diseases including Wolf Hirschhorn syndrome and its overexpression or hyperactivity may Read More …
Background Transcriptional coactivators p300 and CBP catalyze the acetylation of lysine residues of a large variety of histone and non-histone proteins (PMID:28426192). p300 and CBP are considered functional homologous proteins that share around 86% amino acid sequence identity in the HAT domain (PIMID:7870179). The upregulation of p300/CBP has been associated with various cancers, indicating an important role in Read More …
Background RFWD3 (E3 ligase RING finger and WD repeat domain-containing protein 3) and RPA2 (Replication protein A2) were shown to functionally interact and participate in replication checkpoint control. At stalled replication forks, the RPA complex binds single-stranded DNA to prevent nucleolytic digestions and also to initiate replication checkpoint signaling by recruitment checkpoint proteins. RFWD3 is Read More …
Background SMYD3 (SET and MYND domain containing protein 3) is a member of the SMYD lysine methylase family and plays an important role in lysine methylation of various histone and non-histone proteins such as H2A.Z.1-K101, VEDFR1-K831, MAP3K2-K260, HER2-K175 or AKT1-K14. SMYD3 is overexpressed in numerous human tumors and is a potential therapeutic target and prognostic Read More …
In my previous posts (post 1 and post 2), I explained how we found the neighboring residues of the SARS-CoV-2 main protease (MPro) catalytic site, then created a diversity dendrogram of the residues, and looked at three examples of coronavirus MPro structures (SARS-CoV, SARS-CoV-2, MERS). In this post, I explain how we looked at hundreds Read More …
In my previous post, I explained how we found the surrounding residues lining the catalytic site of the SARS-CoV-2 main protease (MPro) using the available crystal structure from the protein databank (PDB code: 7bqy). Following that step, we wanted to zoom in on a few MPro’s structures bound to inhibitors. We looked at MERS, SARS-CoV, Read More …
Many people have spent a few months in quarantine because of the emergence of a novel coronavirus, SARS-CoV-2, the pathogen that causes COVID-19. (1) More people around the globe are fighting this virus as the number of cases increase. As of today, May 19, 2020, the number of confirmed cases globally almost reach five million, Read More …
Background PRMT8 is type I protein arginine methyltransferase expressed mainly in the brain, which mono- and asymmetrically dimethylates histone and nonhistone proteins (Fig.1). It shares over 80% of amino acid sequence homology with PRMT1. At the N-terminus, it harbors a glycine that can be myristoylated which results in its plasma membrane localization (PIMID: 16051612). Fig.1. Read More …
Background PRDM9 (PR domain-containing protein 9) contains a subclass of the SET (PR/SET) domain that trimethylates histone 3 on lysine 4 and 36 (PIMID:24095733). It is expressed mainly in germ cells playing an important role in meiotic recombination (PIMID:27362481). Its aberrant expression has also been associated with genomic instability in cancer (PIMID:30341163). Assay Validation Consistent Read More …
